The histone deacetylase inhibitor itf2357 (givinostat) targets oncogenic braf in melanoma cells and promotes a switch from pro-survival autophagy to apoptosis

HIGHLIGHTS

• who: Adriana Celesia and colleagues from the Department of Biomedicine, Neurosciences and Advanced Diagnostics (BIND), Biochemistry Building, University of Palermo, Palermo, Italy have published the article: The Histone Deacetylase Inhibitor ITF2357 (Givinostat) Targets Oncogenic BRAF in Melanoma Cells and Promotes a Switch from Pro-Survival Autophagy to Apoptosis, in the Journal: Biomedicines 2022, 1994 of 17/08/2022
• what: The authors focus on effects of pan-HDAC (Givinostat) in comparison with SAHA (Vorinostat) in melanoma cells bearing V600E mutation. The authors focused on the effects of ITF2357 on two BRAF V600E mutated cell lines, SK . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.